linjc16/ctgov huggingface dataset:
Tai Chi Training on Hand Grip Strength and Functional Fitness in Post COVID

Study Overview
=================
Brief Summary
-----------------
to evaluate the effects of participating of Tai Chi program on hand grip strength and Functional Fitness in post Covid

Detailed Description
-----------------
evaluate the effects of Tai Chi and aerobic training on improving hand grip strength, fatigue, and functional fitness in patients with post COVID-19.

Official Title
-----------------
A Tai Chi Training on Hand Grip Strength, Fatigue and Functional Fitness in Post COVID in Elderly Patients.

Conditions
-----------------
Post Covid

Intervention / Treatment
-----------------
* Other: tai chi exercise
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: post covid Exclusion Criteria: medically unstable post stroke obese mentally unstable

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: tai chi group<br>patients will receive tai chi exercise program | Other: tai chi exercise<br>* specific tai chi exercise<br>|
| Active Comparator: control group<br>no intervention | Other: no intervention<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hand grip strength | dynamometer Handexer HFEH20 | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| functional fitness | senior fitness tests | 2 months |
The Effect of Exenatide on Fasting Bile Acids

Study Overview
=================
Brief Summary
-----------------
Newly diagnosed T2DM participants without hypoglycemic drugs intake were retrospective analyzed. Plasma total bile acids in fasting state (FTBAs) and other parameters were compared before and after exenatide treatment and correlation analysis between changes of FTBAs and glycemic parameters.

Detailed Description
-----------------
Newly diagnosed T2DM participants without hypoglycemic drugs intake were retrospective analyzed. Plasma total bile acids in fasting state (FTBAs) and other parameters were tested at baseline. Then exenatide were applied to the T2DM participants for 12 weeks. FTBAs and glycemic parameters were measured again after exenatide treatment, and correlation analysis between changes of FTBAs and glycemic parameters were conducted to investigate the role of BAs in the glycemic control effect of exenatide.

Official Title
-----------------
The Effect of Exenatide on Fasting Bile Acids in Newly Diagnosed Type 2 Diabetes Mellitus Patients, a Pilot Study

Conditions
-----------------
Type 2 Diabetes Mellitus in Obese

Intervention / Treatment
-----------------
* Drug: Exenatide treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newly diagnosed T2DM patients Exclusion Criteria: History of hepatobiliary or pancreatic diseases History of anti-diabetic drugs intake Change of anti-dyslipidemia therapy regimen Estimated glomerular filtration rate less than 60 mL/min/1.73 m^2 Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| newly diagnosed T2DM participants<br>newly diagnosed T2DM participants without anti-diabetic drugs intake | Drug: Exenatide treatment<br>* 12 weeks of exenatide injection, 5 μg twice a day by subcutaneous injection for 4 weeks, followed by 10 μg twice a day for 8 weeks, as recommended by the drug manufacturer.<br>* Other names: exenatide;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma total bile acids in fasting state | reported in μmol/L | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fasting plasma glucose | reported in mmol/L | 12 weeks | 
| Glycated hemoglobin A1c | reported in % | 12 weeks | 
| C-peptide | reported in mU/L | 12 weeks | 
| Fasting serum insulin | reported in mU/L | 12 weeks | 
| Body mess index | reported in kg/m^2 | 12 weeks |
Relevance of Biomarkers in the Process of Weaning

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to examine the relevance of biochemical markers (specific pulmonary and cardiac markers and markers of endogenous stress) in the process of weaning in patients with artificial ventilation.

Detailed Description
-----------------
Artificially ventilated patients on our intensive care unit will be monitored if specific biomarkers have a relevance in risk stratification, optimizing therapy, outcome and success in the process of weaning. Therefore, consecutively, specific blood parameters will be taken at time of intubation,day 1 of weaning and extubation.

Official Title
-----------------
The Relevance of Biochemical Markers in the Process of Weaning

Conditions
-----------------
Duration of Weaning

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent Able and willing to understand the protocol At least 18 years or older Exclusion Criteria: Not fulfilling inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| weaning patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| success of weaning | primary outcome measure is the success of weaning during hospital stay. Duration of hospital stay is estimated between 1-60days, in average 30days. Criteria is spontaneous breathing. | participants will be followed for the duration of hospital stay, an expected average of 30days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| follow up | Follow up is done after 12 months to check major adverse cardiac or pulmonary events (death, myocardial infarction, re-hospitalisation) | 12 months |
A Observational Study of Assessment and Treatment Adequacy of Emergency Cancer Pain in Tertiary Cancer Hospital

Study Overview
=================
Brief Summary
-----------------
EMERGENCY CANCER PAIN MANAGEMENT HAS BEEN INCONSISTENT AND INADEQUATE ACROSS THE GLOBE. THIS STUDY AIMS TO KNOW EMERGENCY ROOM CANCER PAIN PATTERNS AND TREATMENT ADEQUACY IN TERTIARY CARE CANCER HOSPITALS.

Official Title
-----------------
A Prospective Observational Study of Assessment of Emergency Cancer Pain and Its Treatment Adequacy in Emergency Department of Tertiary Care Cancer Hospital.

Conditions
-----------------
TO STUDY EMERGENCY CANCER PAIN PATTERNS AND TREATMENT ADEQUACY.

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ADULT CANCER PATIENTS REPORTING TO EMERGENCY ROOM WITH COMPLAINTS PRIMARILY OF PAIN Exclusion Criteria: PATIENTS BELOW 18 YEARS OF AGE AND PATIENTS WITH INCOHERENT BEHAVIOUR.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Observational Study of the Clinical Use of the OCS™ Heart

Study Overview
=================
Brief Summary
-----------------
Single-arm, prospective, multi-center observational study of the clinical use of the ex-vivo perfusion of the heart with the Organ Care System (OCS™)

Detailed Description
-----------------
This is an observational study at two centers that will enroll minimum of 60 heart transplant recipients transplanted with donor heart preserved using the OCS™ Heart System. All consented subjects who receive OCS™-preserved heart transplants will be approached for participation. The study will evaluate short and long-term effectiveness of the OCS™ Heart System for heart transplantation.

Official Title
-----------------
Observational Study of the Clinical Use of the Organ Care System (OCS™) in Heart Transplantation

Conditions
-----------------
Heart Transplantation

Intervention / Treatment
-----------------
* Device: OCS Heart System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All recipients of heart transplantation with Use of the OCS™ Heart Exclusion Criteria: Donor Hearts Presence of coronary heart diseases acute myocardial infarction Presence of heart valve disease (Stenosis or Insufficiency > first degree) Presence of left ventricular hypertrophy (septum and posterior wall thickness >1.7 cm) State of shock of donor (MAP <60 mmHg, CVP >15, PCWP >15 mmHg) with use of Dobutamine >10 ug/kg/min and/or Norepinephrine > 0.5 ug/kg/min or Epinephrine > 0.2 ug/kg/min irreversible persistant pulmonary hypertrophy, defined as transpulmonary gradient >15 mmHg of the recipient
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: OCS Heart System|The OCS™ Heart System is a portable organ perfusion and monitoring medical device intended to preserve donor hearts in a near physiologic and beating state prior to transplantation.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Survival | 12-month patient survival post heart transplant Primary Effectiveness Endpoint | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient and Graft Survival | 30-day patient and graft survival post heart transplant | 30 days |
Impact of Oral Magnesium on Neuropathic Pain

Study Overview
=================
Brief Summary
-----------------
Use lay language. The aim of this study is to evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.

Detailed Description
-----------------
Protocol description Visit D0 patient inclusion after informed signed consent clinical exam blood sampling (magnesium dosage) questionnaires (neuropathic pain and quality of life) daily self-evaluation on neuropathic pain scale (Week0 to Week5) D8 : first intake of study drug (magnesium or placebo) Visit Week5: questionnaires (neuropathic pain and quality of life) blood sampling (magnesium dosage) clinical exam

Official Title
-----------------
Impact of Oral Magnesium on Neuropathic Pain

Conditions
-----------------
Patient With Neuropathic Pain

Intervention / Treatment
-----------------
* Drug: Magnogene ® (magnesium)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - neuropathic pain - informed signed consent Exclusion Criteria: magnesium intake contra-indication severe renal insufficiency quinidine intake concomitant treatment change 2weeks before inclusion evolutive pathology

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Magnogene ® (magnesium)|evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain scores (neuropathic pain evaluation questionnaire) |  | Visit D0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| - Numeric scale - quality o f life questionnaires |  | Visit Week 5 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neuropathic pain, magnesium
Role of NLRP3 in Periodontitis and Diabetes

Study Overview
=================
Brief Summary
-----------------
NLRP3 plays a key role in endothelial function and may be a link for the known interaction of periodontitis and diabetes. The investigators compared the impact of gingival health, periodontitis (CP), diabetes or of both diseases (CP +diabetes) on saliva and serum NLRP3levels.

Detailed Description
-----------------
The aim of this study was to evaluate a possible association between NLRP3 and gingival health, periodontitis (CP), diabetes or of both diseases (CP +diabetes) on saliva and serum NLRP3 levels.

Official Title
-----------------
Evaluation of Serum and Salivary NLRP3 in Periodontitis and Diabetes Patients

Conditions
-----------------
Metabolic Disease, Periodontal Diseases

Intervention / Treatment
-----------------
* Other: Observation of serum and salivary NLRP3 levels


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presence of at least 15 teeth CP with a minimum of 40% of sites with a clinical attachment level (CAL) ≥2mm and probing depth (PD) ≥4mm; Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs Presence of ≥40% sites with bleeding on probing (BOP) Exclusion Criteria: Intake of contraceptives Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study Status of pregnancy or lactation Previous history of excessive drinking Allergy to local anaesthetic Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br>Evaluation of serum and salivary NLRP3 | Other: Observation of serum and salivary NLRP3 levels<br>* Evaluation of serum and salivary NLRP3 levels<br>|
| Periodontitis<br>Evaluation of serum and salivary NLRP3 | Other: Observation of serum and salivary NLRP3 levels<br>* Evaluation of serum and salivary NLRP3 levels<br>|
| Diabetes<br>Evaluation of serum and salivary NLRP3 | Other: Observation of serum and salivary NLRP3 levels<br>* Evaluation of serum and salivary NLRP3 levels<br>|
| Periodontitis + diabetes<br>Evaluation of serum and salivary NLRP3 | Other: Observation of serum and salivary NLRP3 levels<br>* Evaluation of serum and salivary NLRP3 levels<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical attachment level | evaluation of changes in clinical attachment level | 1-year |
Adrenal Function in Patients With Newly Diagnosed Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Patients with newly diagnosed lung cancer may have hypofunction of the adrenal cortex either from tumour metastasis or other mechanisms. Since lung cancer patient may have to undergo stressful investigation and treatments, undetected hypofunction of the adrenal cortex may be hazardous. Knowledge of the size of the problem may help determine whether routine check is warranted.

Official Title
-----------------
Adrenal Cortical Function in Patients With Newly Diagnosed Lung Cancer

Conditions
-----------------
Lung Cancer, Adrenal Insufficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically proven primary lung cancer Newly diagnosed No specific treatment given No active infection in the previous week No general anesthesia in the previous week Exclusion Criteria: Known adrenal disease Receiving exogenous systemic corticosteroids Concomitant illness known to affect adrenal function. e.g. active TB

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adrenal insufficiency, lung cancer
Clinical Evaluation of Chairside CAD/CAM Nano-ceramic Restorations

Study Overview
=================
Brief Summary
-----------------
Study aim is to test whether nano-composite CAD/CAM milled restorations have a similar performance in clinical service to conventional ceramic CAD/CAM restorations.

Official Title
-----------------
Clinical Evaluation of Chairside CAD/CAM Nano-ceramic Restorations

Conditions
-----------------
Restoration of Posterior Teeth

Intervention / Treatment
-----------------
* Device: Milled ceramic restorations
* Device: Milled nano-composite restorations


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient 18 years of age or over To have at least one carious lesion or defective restoration in a molar or premolar tooth, cavities to be large enough to warrant a milled restoration of either a crown or onlay Teeth to be vital and asymptomatic Exclusion Criteria: Devital or sensitive teeth Teeth that have had root canal treatment Patients with significant untreated dental disease including periodontitis and rampant caries Pregnant or lactating women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| nano-composite<br>crowns and onlays | Device: Milled nano-composite restorations<br>* Restoration of back teeth with milled crowns or onlays<br>* Other names: Lava Ultimate CAD/CAM Restorative (3M ESPE);|
| ceramic<br>crowns & onlays | Device: Milled ceramic restorations<br>* Restoration of back teeth with milled ceramic crowns or onlays<br>* Other names: Empress CAD/CAM leucite porcelain (Ivoclar Vivadent);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical performance | Subjective evaluation of restorations using USPHS criteria | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Luting cement | Subjective evaluaton of performance of a nano-filled resin luting cement used to cement the study onlays | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CAD/CAM, crowns, onlays, composite block, milled restorations
Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether erythropoietin is effective in preventing acute kidney dysfunction after coronary artery bypass grafting surgery.

Detailed Description
-----------------
Acute kidney injury (AKI) occurs in 7% to 40% of patients undergoing cardiac surgery, depending on the definition of AKI used. Even small increments in serum creatinine have been shown to be associated with increased mortality after cardiac surgery. However, there are no proven interventions to prevent AKI after cardiac surgery. Erythropoietin (EPO) has been shown to have tissue-protective effects in various experimental models. In this prospective placebo-controlled randomized trial, we evaluated the effectiveness of EPO in the prevention of AKI after coronary artery bypass grafting (CABG).

Official Title
-----------------
Prevention of Acute Kidney Injury (AKI) by Erythropoietin (EPO) in Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery - A Prospective Placebo-Controlled Randomized Trial

Conditions
-----------------
Kidney Failure, Acute

Intervention / Treatment
-----------------
* Drug: Erythropoietin-Beta
* Drug: Normal Saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for elective CABG over age 18 Exclusion Criteria: Under age 18 Emergent CABG Prior exposure to nephrotoxic drug Dialysis patients Uncontrolled hypertension

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: EPO group<br> | Drug: Erythropoietin-Beta<br>* 300 IU/kg of EPO or saline intravenously before surgery<br>* Other names: recormon;|
| Placebo Comparator: Placebo group<br> | Drug: Normal Saline<br>* 300 IU/kg of normal saline intravenously before surgery<br>* Other names: 0.9% saline;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants Who Had AKI (Acute Kidney Injury) | number of participants who had 50% increase in serum creatinine levels from baseline | at any time within the first 5 days after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Estimated Glomerular Filtration Rate (eGFR) | estimated glomerular filtration rate (eGFR)as ml/min/1.73m2 | during the first 5 days after surgery |